Dr Martin Gagnon
Director, Research and Enterprise Office – University of Otago
Martin joined Otago in 2018, bringing with him his extensive experience in research funding acquired in Canada. Martin spent the last 5 years at Exactis Innovation, a pan-Canadian clinical research network he helped create, funded jointly by the federal government’s Network of Centres of Excellence program and industry partners. Martin brings strategic and operational expertise having secured more than $100M in research financing over the past 10 years.
Previously, he co-founded Chlorion Pharma, a neuroscience-focused biotechnology company. As Chief Operating Officer and Vice President of Research, Martin validated the neuronal cation-chloride co-transporter KCC2 as a novel target for the treatment of neuropathic pain and epilepsy and successfully raised several million from venture capital funds to support drug development activities.
Martin obtained a Ph.D. in pharmacology and therapeutics from McGill University. His doctoral work in rational drug design led to the development of novel cancer therapeutics and allosteric inhibitors of protein tyrosine phosphatases.